Corteva, Inc., through its Corteva Catalyst platform, led a $6.1 million investment in IBI Ag, marking the first tranche of the company's Series A funding round. IBI Ag is a crop protection company focused on developing bio-insecticides with a lower ecological footprint. This investment underscores the strategic importance of biological and naturally-inspired solutions in the global agricultural sector.
IBI Ag's technology leverages single domain antibodies, adapted from the pharmaceutical industry, to create highly effective crop protection solutions with novel modes of action. These products are designed to target a broad spectrum of insects while minimizing impact on non-targeted organisms. The company plans to initially target high-value crops before expanding to row crop solutions.
The capital infusion will accelerate the development of IBI Ag's single domain antibody technology, providing farmers with sustainable and effective crop protection solutions. Corteva's investment aligns with its strategic focus on accelerating the development of next-generation biological and naturally-inspired solutions to enhance agricultural productivity and environmental preservation.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.